mRNA vaccines
Showing 1 - 25 of 3,239
Pancreatic Cancer Trial in Shanghai (Adebrelimab, mRNA tumor vaccines)
Not yet recruiting
- Pancreatic Cancer
- Adebrelimab
- mRNA tumor vaccines
-
Shanghai, Shanghai, ChinaDepartment of Pancreatic Surgery, Fudan University Shanghai Canc
Dec 4, 2023
SARS-CoV-2 Trial (CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose)
Not yet recruiting
- SARS-CoV-2
- CV0701 Bivalent High dose
- +4 more
- (no location specified)
Jul 24, 2023
COVID-19 Trial in United States (NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant)
Active, not recruiting
- COVID-19
- NVX-CoV2373
- SARS-CoV-2 rS antigen/Matrix-M Adjuvant
-
Austin, Texas
- +4 more
May 16, 2023
COVID-19 Trial in Jakarta (ABO1009-DP, ABO-CoV.617.2, Placebo)
Recruiting
- COVID-19
- ABO1009-DP
- +2 more
-
Jakarta, Indonesia
- +1 more
Jul 25, 2022
Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)
Not yet recruiting
- Immunogenicity
- Safety
- Phase II:SWIM816;SARS-Cov-2;
- +3 more
- (no location specified)
Jun 18, 2023
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus Trial in United States (mRNA-1273, mRNA-1010, mRNA-1345)
Recruiting
- SARS-CoV-2
- +3 more
- mRNA-1273
- +4 more
-
Hollywood, Florida
- +7 more
May 25, 2022
HIV Trial in United States (BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA)
Suspended
- HIV Infections
- BG505 MD39.3 mRNA
- +2 more
-
Birmingham, Alabama
- +9 more
Feb 1, 2023
COVID-19 Trial (Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine
Not yet recruiting
- COVID-19
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
- +2 more
- (no location specified)
Jul 5, 2022
Influenza Trial in South Jordan (mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only)
Recruiting
- Influenza
- mRNA-1018 for H5N8
- +4 more
-
South Jordan, UtahJ. Lewis Research, Inc/Jordan River Family Medicine
Jul 25, 2023
First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney
Active, not recruiting
- Kidney Diseases
- +5 more
- Booster dose of mRNA vaccine
-
Praha, CzechiaInstitute for Clinical and Experimental Medicine
Aug 2, 2022
Advanced Solid Tumor Trial in Shanghai (Personalized neoantigen tumor vaccine)
Recruiting
- Advanced Solid Tumor
- Personalized neoantigen tumor vaccine
-
Shanghai, Shanghai, ChinaRuijin Hospital Shanghai Jiaotong University School of Medicine
Jun 24, 2023
Advanced Pancreatic Cancer Trial in Qionghai (Personalized neoantigen tumor vaccine)
Recruiting
- Advanced Pancreatic Cancer
- Personalized neoantigen tumor vaccine
-
Qionghai, Hainan, ChinaRuijin-Hainan Hospital Affiliated to Shanghai Jiao Tong Universi
Jun 14, 2023
SafeTy and Efficacy of Preventative CoVID Vaccines
Active, not recruiting
- COVID-19 Virus Infection
- Vaccine Response
- mRNA Vaccines or Viral vector-based vaccines for COVID
-
Toronto, Ontario, CanadaUniversity Health Network
May 19, 2022
COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))
Not yet recruiting
- COVID-19
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
- Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- (no location specified)
Aug 4, 2023
Seasonal Influenza Trial in United States (mRNA-1011.1, mRNA-1011.2, mRNA-1012.1)
Recruiting
- Seasonal Influenza
- mRNA-1011.1
- +5 more
-
Lakewood, California
- +21 more
Apr 12, 2023
Fever After Vaccination, Fever, Seizures Fever Trial in United States (Pfizer-BioNTech COVID-19 Vaccine, Routine Childhood
Not yet recruiting
- Fever After Vaccination
- +2 more
- Pfizer-BioNTech COVID-19 Vaccine
- Routine Childhood Vaccinations
-
Oakland, California
- +4 more
Sep 8, 2023
Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose Trial in Paris
Active, not recruiting
- Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose
- Pfizer
- Moderna
-
Paris, FranceCIC 1417 Cochin-Pasteur
Jul 31, 2021
Seasonal Influenza Trial in United States (mRNA-1030, mRNA-1020, mRNA-1010)
Completed
- Seasonal Influenza
- mRNA-1030
- +3 more
-
Phoenix, Arizona
- +14 more
Dec 5, 2022
Immune Response, Safety Trial in Incheon (bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine, quadrivalent influenza
Active, not recruiting
- Immune Response
- Safety
- bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
- quadrivalent influenza vaccine
-
Incheon, Seo-gu, Korea, Republic ofInternational St. Mary's hospital
Jul 28, 2023
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection Trial (Novavax COVID-19 vaccine (2023-2024 formula XBB containing),
Not yet recruiting
- COVID-19
- +4 more
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing)
- Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- (no location specified)
Sep 29, 2023
Influenza Trial in Saint Louis (mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine)
Recruiting
- Influenza
- mRNA-1010
- +3 more
-
Saint Louis, MissouriWashington University in St. Louis
Nov 4, 2022
COVID-19 Trial in Bizerte, Ariana, Tunis (CoronaVac/CoronaVac, CoronaVac/BNT162b2)
Completed
- COVID-19
- CoronaVac/CoronaVac
- CoronaVac/BNT162b2
-
Bizerte, Mateur, Tunisia
- +4 more
Jan 4, 2023
SARS-CoV-2, Influenza, RSV Trial in Australia, United Kingdom, United States (mRNA-1010, mRNA-1345, mRNA-1273.214)
Recruiting
- SARS-CoV-2
- +2 more
- mRNA-1010
- +4 more
-
DeLand, Florida
- +29 more
Jan 23, 2023
SARS-CoV-2 Trial in Melbourne (Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59),
Recruiting
- SARS-CoV-2
- Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
- +2 more
-
Melbourne, Victoria, Australia
- +1 more
Apr 25, 2022